NHS Introduces One-Minute Immunotherapy Injection for Cancer Patients, Replacing Hour-Long Infusions

The NHS in England has announced a significant upgrade in cancer treatment delivery, offering thousands of patients a one-minute injection of the immunotherapy drug pembrolizumab instead of the traditional infusion that takes hours. This change, which applies to the drug marketed as Keytruda, is expected to streamline treatment for various cancers, including melanoma, lung cancer, and other solid tumors. The subcutaneous injection, administered in just one to two minutes, replaces the intravenous infusion that previously required patients to spend significant time in hospital.

Pembrolizumab is a checkpoint inhibitor that helps the immune system recognize and attack cancer cells. By switching from intravenous to subcutaneous administration, the NHS aims to reduce patient burden, free up hospital resources, and improve overall treatment experience. The rollout is part of a broader effort to modernize cancer care and increase efficiency within the health service.

For companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which are also engaged in developing innovative cancer therapies, this shift underscores the growing trend toward more convenient and patient-friendly treatment modalities. Calidi Biotherapeutics focuses on oncolytic virus-based immunotherapies, and the NHS's adoption of a faster administration method highlights the potential for similar advancements in other immunotherapy platforms.

The decision to offer the injection follows clinical trials demonstrating that subcutaneous pembrolizumab is as effective as the intravenous version, with comparable safety profiles. Patients will now be able to receive their treatment more quickly, reducing the time spent in clinical settings and allowing them to return to their daily lives sooner. This is particularly beneficial for those who require frequent dosing, as it minimizes disruption to work, family, and other commitments.

Healthcare professionals have welcomed the change, noting that it could lead to increased patient satisfaction and adherence to treatment plans. The shorter administration time also allows hospitals to accommodate more patients each day, potentially reducing waiting lists for cancer therapy. The NHS expects the new injection to be available across England in the coming months, with training provided to staff to ensure safe and effective administration.

The move is part of a larger trend in oncology toward personalized and convenient care. As research continues to evolve, more drugs may become available in subcutaneous or oral forms, further transforming the cancer treatment landscape. For now, the NHS's adoption of the pembrolizumab injection represents a practical step forward in improving the lives of cancer patients while optimizing healthcare delivery.